Neuronetics today priced its upcoming initial public offering, expecting to raise approximately $93.5 million to support its NeuroStar transcranial magnetic stimulation system designed to treat patients with major depressive disorder who aren’t responding to medication.
The Malvern, Penn.-based company said it is looking to float 5.5 million shares of its common stock at $17 per share in its IPO. The offering also includes a 30-day underwriter’s option to purchase an additional 825,000 shares, which could net an additional $14.5 million for the company.
Shares are expected to begin trading today under the ticker symbol “STIM”, Neuronetics said, and is expected to close on July 2, according to a press release.
The company’s NeuroStar device uses MRI-strength magnetic fields to stimulate specific areas of the brain associated with mood. The device initially won 510(k) clearance from the FDA in December 2008, for treating adults with major depressive disorder who previously failed to respond to one medication. The federal safety watchdog expanded NeuroStar’s indication in May 2014 to cover adult patients who failed to respond to one or more medications in their current depressive episode.
There are 781 NeuroStar installations across 615 psychiatry practices, with some 50,000 patients treated in roughly 1.8 million sessions, the company said in its SEC filing. The company reported losses last year of -$16.1 million, or -$2.97 per share, on sales of $40.4 million, increased its red ink by 42.9% on sales growth of 18.1% compared with 2016.
First-quarter losses grew 21.8% to -$5.5 million, or -84¢ per share, on sales of $10.2 million for the three months ended March 31, for a top-line gain of 34.9% compared with Q1 2017.
The company registered for the IPO earlier this month, with Piper Jaffray and William Blair & Co. maned as joint book-runners and Canaccord Genuity and JMP Securities as co-managers.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.